cyprotex
the ADME Tox specialists
home > ADME and PK services > Caco-2 permeability

Caco-2 permeability assay

Understand the suitability of your compound for oral dosing by using our Caco-2 permeability assay to predict human intestinal permeability and to investigate drug efflux.

Caco-2 permeability is included in our portfolio of in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.

 

Caco-2 permeability assay to investigate intestinal permeability

  • Cyprotex's Caco-2 Permeability assay uses an established method for predicting the in vivo absorption of drugs across the gut wall by measuring the rate of transport of a compound across the Caco-2 cell line.
  • The Caco-2 cell line is derived from a human colon carcinoma. The cells have characteristics that resemble intestinal epithelial cells such as the formation of a polarized monolayer, well-defined brush border on the apical surface and intercellular junctions.
  • Assessing transport in both directions (apical to basolateral (A-B) and basolateral to apical (B-A)) across the cell monolayer enables an efflux ratio to be determined which provides an indicator as to whether a compound undergoes active efflux.
  • The P-glycoprotein (P-gp) inhibitor, verapamil, can be included to identify whether active transport is mediated by P-gp.
  caco-2 permeability assay
‘Studying the permeability of compounds across a Caco-2 cell monolayer is an established in vitro model to screen for oral absorption and to evaluate the mechanism of transport. Using LC-MS/MS for the analysis of samples derived from Caco-2 cell studies allows the rapid and accurate determination of drug transport across the Caco-2 cell monolayer.’
1Wang Z, Hop C.E., Leung K.H. and Pang J. (2000) J Mass Spectrom 35 (1); 71-6
Protocol +
Data +
Q&A +
References

1 Wang Z et al. (2000) J Mass Spectrom. 35 (1); 71-6
2 Zhao YH et al. (2001) J Pharmaceut Sci 90; 749-784

3 Yazdanian M et al. (1998) Pharmaceut Res 15; 1490-1494
4 Kansy M et al. (2001) Pharmacokinetic optimisation in drug research Ed. Testa et al; 447-464

 
Caco-2 permeability

Download a copy of the product sheet

Cloe® is a registered trade mark owned by Cyprotex PLC

careerscontactlegalprivacy
This website was last updated
on 16th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.